131 related articles for article (PubMed ID: 12920852)
1. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results.
Wells JM; Mankoff DA; Eary JF; Spence AM; Muzi M; O'Sullivan F; Vernon CB; Link JM; Krohn KA
Mol Imaging; 2002 Jul; 1(3):145-50. PubMed ID: 12920852
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis.
Wells JM; Mankoff DA; Muzi M; O'Sullivan F; Eary JF; Spence AM; Krohn KA
Mol Imaging; 2002 Jul; 1(3):151-9. PubMed ID: 12920853
[TBL] [Abstract][Full Text] [Related]
3. 2-[C-11]thymidine imaging of malignant brain tumors.
Eary JF; Mankoff DA; Spence AM; Berger MS; Olshen A; Link JM; O'Sullivan F; Krohn KA
Cancer Res; 1999 Feb; 59(3):615-21. PubMed ID: 9973209
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies.
Mankoff DA; Shields AF; Link JM; Graham MM; Muzi M; Peterson LM; Eary JF; Krohn KA
J Nucl Med; 1999 Apr; 40(4):614-24. PubMed ID: 10210220
[TBL] [Abstract][Full Text] [Related]
5. [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions.
De Reuck J; Santens P; Goethals P; Strijckmans K; Lemahieu I; Boon P; Achten E; Lemmerling M; Vandekerckhove T; Caemaert J
Acta Neurol Belg; 1999 Jun; 99(2):118-25. PubMed ID: 10427354
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis.
Mankoff DA; Shields AF; Graham MM; Link JM; Eary JF; Krohn KA
J Nucl Med; 1998 Jun; 39(6):1043-55. PubMed ID: 9627342
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
9. Brain tumor imaging with PET and 2-[carbon-11]thymidine.
Vander Borght T; Pauwels S; Lambotte L; Labar D; De Maeght S; Stroobandt G; Laterre C
J Nucl Med; 1994 Jun; 35(6):974-82. PubMed ID: 8195884
[TBL] [Abstract][Full Text] [Related]
10. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
11. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds.
Shields AF; Graham MM; Kozawa SM; Kozell LB; Link JM; Swenson ER; Spence AM; Bassingthwaighte JB; Krohn KA
J Nucl Med; 1992 Apr; 33(4):581-4. PubMed ID: 1552344
[TBL] [Abstract][Full Text] [Related]
12. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.
Shields AF; Mankoff D; Graham MM; Zheng M; Kozawa SM; Link JM; Krohn KA
J Nucl Med; 1996 Feb; 37(2):290-6. PubMed ID: 8667064
[TBL] [Abstract][Full Text] [Related]
13. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography.
Martiat P; Ferrant A; Labar D; Cogneau M; Bol A; Michel C; Michaux JL; Sokal G
J Nucl Med; 1988 Oct; 29(10):1633-7. PubMed ID: 3262725
[TBL] [Abstract][Full Text] [Related]
14. Utilization of labeled thymidine in DNA synthesis: studies for PET.
Shields AF; Lim K; Grierson J; Link J; Krohn KA
J Nucl Med; 1990 Mar; 31(3):337-42. PubMed ID: 2308005
[TBL] [Abstract][Full Text] [Related]
15. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
16. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies.
Wells P; Gunn RN; Alison M; Steel C; Golding M; Ranicar AS; Brady F; Osman S; Jones T; Price P
Cancer Res; 2002 Oct; 62(20):5698-702. PubMed ID: 12384527
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
[TBL] [Abstract][Full Text] [Related]
18. Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors.
Juhász C; Muzik O; Chugani DC; Chugani HT; Sood S; Chakraborty PK; Barger GR; Mittal S
J Neurooncol; 2011 May; 102(3):409-15. PubMed ID: 20676727
[TBL] [Abstract][Full Text] [Related]
19. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Muzi M; Mankoff DA; Grierson JR; Wells JM; Vesselle H; Krohn KA
J Nucl Med; 2005 Feb; 46(2):371-80. PubMed ID: 15695799
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography imaging of brain tumors.
Wong TZ; van der Westhuizen GJ; Coleman RE
Neuroimaging Clin N Am; 2002 Nov; 12(4):615-26. PubMed ID: 12687915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
